SMART2D intervention

1. SMART2D intervention impairs glycaemic control in humans (adjusted IRR=0.92, 95% CI=0.89-0.95).

   Human trialparticipants with T2Dn = 58

   Proof-of-implementation of the SMART2D intervention: findings from a cluster randomised feasibility trial for prevention and control of type 2 diabetes in socio-economically disadvantaged neighbourhoods in Stockholm, Sweden · medRxiv · 2 Oct 2026 · Preprint

1. SMART2D intervention improves retention to care in humans (adjusted IRR=1.22, 1.15-1.29).

   Human trialparticipants at high risk of T2Dn = 84

   Proof-of-implementation of the SMART2D intervention: findings from a cluster randomised feasibility trial for prevention and control of type 2 diabetes in socio-economically disadvantaged neighbourhoods in Stockholm, Sweden · medRxiv · 2 Oct 2026 · Preprint

1. SMART2D intervention increases HbA1c reduction in humans (adjusted 2.02, 0.20-3.84).

   Human trialparticipants at high risk of T2Dn = 84

   Proof-of-implementation of the SMART2D intervention: findings from a cluster randomised feasibility trial for prevention and control of type 2 diabetes in socio-economically disadvantaged neighbourhoods in Stockholm, Sweden · medRxiv · 2 Oct 2026 · Preprint

HbA1c reduction →

1. SMART2D intervention lowers the risk of type 2 diabetes in humans (0 vs. 2).

   Human trialparticipants at high risk of T2Dn = 84

   Proof-of-implementation of the SMART2D intervention: findings from a cluster randomised feasibility trial for prevention and control of type 2 diabetes in socio-economically disadvantaged neighbourhoods in Stockholm, Sweden · medRxiv · 2 Oct 2026 · Preprint

Type 2 diabetes →